Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2013
10/31/2013WO2013161895A1 Bone repair promoter
10/31/2013WO2013161471A1 Medicament for treating mental and behavioural disorders
10/31/2013WO2013160222A1 Treatment method for steroid responsive dermatoses
10/31/2013WO2013111066A3 Pharmaceutical compositions containing phosphatidylserine and curcumin
10/31/2013WO2008089439A3 Methods and compositions for enhancing lifespan involving sirtuin-modulating compounds and chalcogenides
10/31/2013WO2002078598A3 Peptides and antibodies to muc 1 proteins
10/31/2013US20130289131 Injectable pharmaceutical compositions for the treatment of joints
10/31/2013US20130289127 Aminoalkanol derivatives
10/31/2013US20130289107 Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol
10/31/2013US20130289103 Anti-microbial composition
10/31/2013US20130289098 Compositions and methods for treatment of ovarian cancer
10/31/2013US20130289074 New indanyloxydihydrobenzofuranylacetic acids
10/31/2013US20130289073 Chemical inhibitors of cholesterol biosynthesis and venous angiogenesis
10/31/2013US20130289070 Use of Levocabastine for Modulating Generation of Pro-Inflammatory Cytokines
10/31/2013US20130289068 Enhanced migraine treatments based on ghrelin mimetics
10/31/2013US20130289059 Beneficial effects of increasing local blood flow
10/31/2013US20130289058 Cyclic bridgehead ether dgat1 inhibitors
10/31/2013US20130289046 Pharmaceutical formulations of substituted azaindoleoxoacetic piperazine derivatives with protease inhibitors
10/31/2013US20130289029 Fused Ring Compound For Use As Mineralocorticoid Receptor Antagonist
10/31/2013US20130289027 Isoquinoline Compounds And Methods For Treating HIV
10/31/2013US20130289023 Method for treating brain tumor
10/31/2013US20130289022 Tetrameric alpha-synuclein and use thereof
10/31/2013US20130289021 Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction
10/31/2013US20130289017 5 (1,2,3-triazol-4-yl)-7h-pyrrolo[2,3-d]pyrimidine derivatives
10/31/2013US20130289016 Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
10/31/2013US20130289014 Combination therapy in treatment of oncological and fibrotic diseases
10/31/2013US20130289010 1-phenyl-2-pyridinyl alkyl alcohol compounds as phosphodiesterase inhibitors
10/31/2013US20130288997 Nucleoside phosphoramidates
10/31/2013US20130288987 Melanocortin Receptor-Specific Peptides for Treatment of Female Sexual Dysfunction
10/31/2013US20130288985 Compositions and methods of treatment of corneal endothelium disorders
10/31/2013US20130288979 Inhibitors of Apoptosis and Uses Thereof
10/31/2013US20130288965 Use of peptides for promoting wound healing
10/31/2013US20130288950 Use of tight junction antagonists in the treatment of acute lung injury and acute respiratory distress
10/31/2013US20130287866 Nitric Oxide Amino Acid Esters for Improving Vascular Circulation, and Prophylaxis or Treatment of a Condition Associated with Impaired Blood Circulation
10/31/2013US20130287854 Compositions and uses
10/31/2013US20130287821 Pharmaceutical formulation for reducing frequency of urination and method of use thereof
10/31/2013US20130287806 Immune-modulating agents and uses therefor
10/31/2013US20130287803 Novel uses of vegfxxxb
10/31/2013US20130287789 Organic Compounds
10/31/2013US20130287784 Compositions Targeting the Soluble Extracellular Domain of E-Cadherin and Related Methods for Cancer Therapy
10/31/2013US20130287779 Humanized anti-egfl7 antibodies and methods using same
10/31/2013US20130287769 Treatment of solid tumors with rapamycin derivatives
10/31/2013US20130287767 Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof
10/31/2013US20130287763 Combination therapy for treating cancer comprising an igf-1r inhibitor and an akt inhibitor
10/31/2013US20130287760 Treatment for dupuytren's disease
10/31/2013US20130287756 Composition and method to alleviate joint pain
10/31/2013US20130287747 Methods of Treating Acute Kidney Injury Using Mesenchymal Stem Cells
10/31/2013US20130287731 Hepatitis c virus inhibitors
10/31/2013US20130287730 Piperazine-piperidine compounds as hepatitis c virus inhibitors
10/31/2013US20130287728 Compositions and Methods for Treating Progressive Myocardial Injury Due to A Vascular Insufficiency
10/31/2013US20130287708 Natural formulations
10/31/2013US20130287688 Novel compositions and uses of anti-hypertension agents for cancer therapy
10/31/2013DE202011110413U1 Zusammensetzung zum Verzögern und Verbessern einer photoinduzierten Netzhautschädigungund von Katarakten unter Verbesserung eines Xerophthalmiesyndroms unter Verwendung vonOmega-Cholin Composition for delaying and improving a photoinduced Netzhautschädigungund of cataracts with improvement of Xerophthalmiesyndroms using vonOmega-choline
10/30/2013EP2657236A1 Novel 2-alkynyl-n9-propargyladenine and medicinal use thereof
10/30/2013EP2657235A1 Compound containing basic group and use thereof
10/30/2013EP2656858A1 Transpulmonary liposome for controlling drug arrival
10/30/2013EP2656855A2 Pharmaceutical preparation for the treatment of depressive pathologies, comprising a protein with a high tryptophan-LNAAs (Large Neutral Amino Acids) ratio
10/30/2013EP2655665A1 Single nucleotide polymorphisms and genes associated with t2d-related complications
10/30/2013EP2654899A1 Methods for treating neurological conditions and compositions and materials therefor
10/30/2013EP2654898A1 Modulators of trpa1 for the treatment of rosacea
10/30/2013EP2654777A2 Methods and compositions suitable for managing blood glucose in animals
10/30/2013EP2654758A1 A composition comprising at least two compounds which induces indolamine 2,3-dioxygenase (ido), for the treatment of an autoimmune disorder or suffering from immune rejection of organs
10/30/2013EP2654757A1 The use of spinosyns and spinosyn compositions as local anesthetics and as antiarrhythmic agents
10/30/2013EP2654745A1 Composition for the treatment of skin conditions
10/30/2013EP2654743A1 Combination comprising d-apartic acid and l-arginine or salts thereof for the improvement of cognitive activities and memory in dementia such as dementia senile and alzheimer's disease
10/30/2013EP2654727A1 Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
10/30/2013EP2654637A1 Kit-in-parts for cleaning and treating ears of companion animals
10/30/2013CN1264307B Method of enhancing function of upper gastrointestinal tract
10/30/2013CN103374042A Dynamic anti-cancer platinum compound with two different ligands at syn-position
10/30/2013CN103372220A Pharmaceutical microsphere for embolization
10/30/2013CN103372218A microRNA related to autoimmune disease and application thereof
10/30/2013CN103372215A Composition and methods used during anti-hiv treatment
10/30/2013CN103372214A Pharmaceutical composition for treating and/or preventing insulin dependent diabetes mellitus and application thereof
10/30/2013CN103372213A Application of inhibitors of phospholipid scramblases (plscrs) for preparing medicine for the prophylactic or therapeutic treatment of cancers
10/30/2013CN103372212A Quinazoline molecular targeted medicinal composition
10/30/2013CN103372211A Antiviral compound preparation for fish
10/30/2013CN103372210A Application of berberine combined chemotherapeutic medicament in antitumor therapy
10/30/2013CN103372015A Pessulum preparation containing drospirenone or drospirenone and estrogen
10/30/2013CN103371992A Application of (E)-nitrogen-(4-cinnamamide butyl)benzamide in preparing anti-tumor medicaments
10/30/2013CN103371974A Drug sustained release polymeric microspheres prepared based on micro-fluidic technology and application
10/30/2013CN102378627B Antibacterial composition comprising 4 -isopropyl-3-methylpheno and zinc ions
10/30/2013CN102274160B Method and preparation for treating resistance to antihypertensives and related conditions
10/30/2013CN101970008B Palatable solid composition comprising antacid and saliva stimulant
10/30/2013CN101472476B Treating obesity with muscarinic receptor M1 antagonists
10/30/2013CN101257946B Pharmaceutical dosage form containing active principle combination of nifedipine and/or nisoldipine and of angiotensin II antagonist
10/29/2013US8569347 Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
10/29/2013US8569332 O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders
10/29/2013US8569325 Method of treatment with coadministration of aspirin and prasugrel
10/29/2013US8569058 Nerve regeneration promoters
10/29/2013US8568972 Substances causing differentiation
10/29/2013US8568805 Cognitive function
10/29/2013US8568792 Metal compounds, mixed or sulphated, as phosphate binders
10/29/2013US8568742 Methods and compositions involving immunostimulatory oligodeoxynucleotides
10/29/2013US8568738 Virus-modified bacteria ghosts
10/29/2013US8568449 High strength suture with absorbable core and suture anchor combination
10/29/2013CA2700242C Use of a combination of an opioid agonist and an opioid antagonist for the treatment of crohn's disease and the symptoms associated with crohn's disease
10/29/2013CA2458001C Regulation of immune responses by manipulation of intermediary metabolite levels
10/29/2013CA2442363C Reducing the immunogenicity of fusion proteins
10/29/2013CA2434643C Peptides for activation and inhibition of.delta.pkc
10/24/2013WO2013158961A1 Combination of a non-steroidal anti-inflammatory drug with an anti-histaminic drug intended for ophthalmic use
1 ... 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 ... 1151